120 related articles for article (PubMed ID: 7541424)
1. Chimeric horse/human recombinant C9 proteins identify the amino acid sequence in horse C9 responsible for restriction of hemolysis.
Tomlinson S; Wang Y; Ueda E; Esser AF
J Immunol; 1995 Jul; 155(1):436-44. PubMed ID: 7541424
[TBL] [Abstract][Full Text] [Related]
2. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
4. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
Husler T; Lockert DH; Sims PJ
Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
[TBL] [Abstract][Full Text] [Related]
5. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
[TBL] [Abstract][Full Text] [Related]
6. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex.
Huang Y; Fedarovich A; Tomlinson S; Davies C
Acta Crystallogr D Biol Crystallogr; 2007 Jun; 63(Pt 6):714-21. PubMed ID: 17505110
[TBL] [Abstract][Full Text] [Related]
8. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
9. Recombinant soluble CD59 inhibits reactive haemolysis with complement.
Sugita Y; Ito K; Shiozuka K; Suzuki H; Gushima H; Tomita M; Masuho Y
Immunology; 1994 May; 82(1):34-41. PubMed ID: 7519172
[TBL] [Abstract][Full Text] [Related]
10. Mapping the regions of the complement inhibitor CD59 responsible for its species selective activity.
Yu J; Dong S; Rushmere NK; Morgan BP; Abagyan R; Tomlinson S
Biochemistry; 1997 Aug; 36(31):9423-8. PubMed ID: 9235986
[TBL] [Abstract][Full Text] [Related]
11. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59.
Hüsler T; Lockert DH; Kaufman KM; Sodetz JM; Sims PJ
J Biol Chem; 1995 Feb; 270(8):3483-6. PubMed ID: 7533152
[TBL] [Abstract][Full Text] [Related]
12. Identification of the discontinuous epitope in human complement protein C9 recognized by anti-melittin antibodies.
Laine RO; Esser AF
J Immunol; 1989 Jul; 143(2):553-7. PubMed ID: 2472443
[TBL] [Abstract][Full Text] [Related]
13. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
Deng J; Gold D; LoVerde PT; Fishelson Z
Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
[TBL] [Abstract][Full Text] [Related]
14. The role of the C9b domain in the binding of C9 molecules to EAC1-8 defined by monoclonal antibodies to C9.
Yoden A; Moriyama T; Inoue K; Inai S
J Immunol; 1988 Apr; 140(7):2317-21. PubMed ID: 3351301
[TBL] [Abstract][Full Text] [Related]
15. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
16. Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity.
Taylor KM; Morgan BP; Campbell AK
Immunology; 1994 Nov; 83(3):501-6. PubMed ID: 7835977
[TBL] [Abstract][Full Text] [Related]
17. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
Chang CP; Hüsler T; Zhao J; Wiedmer T; Sims PJ
J Biol Chem; 1994 Oct; 269(42):26424-30. PubMed ID: 7523406
[TBL] [Abstract][Full Text] [Related]
18. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
Tschopp J; Chonn A; Hertig S; French LE
J Immunol; 1993 Aug; 151(4):2159-65. PubMed ID: 8345200
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
Davé SJ; Sodetz JM
J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
[TBL] [Abstract][Full Text] [Related]
20. Functional studies of the MACPF domain of human complement protein C8alpha reveal sites for simultaneous binding of C8beta, C8gamma, and C9.
Slade DJ; Chiswell B; Sodetz JM
Biochemistry; 2006 Apr; 45(16):5290-6. PubMed ID: 16618117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
